Ubiquinol improves arterial health to support blood circulation
Ubiquinol significantly improves endothelial function1
In an 8-week, randomized, double-blind, single-center trial, with the primary outcome of change in flow-mediated dilation (FMD) in healthy patients with mild-to-moderate dyslipidemia, Ubiquinol significantly improved dyslipidemia-related endothelial dysfunction (P=0.001).
*Response with Ubiquinol was dose-independent.
†No significant changes in plasma lipid profile between groups or versus baseline for either group (one-way ANOVA, P=0.905). Ubiquinol improved endothelium-dependent vasodilation independent of plasma cholesterol levels.
Significant improvements on 3 secondary endpoints
- Ubiquinol increased plasma CoQ10 levels versus placebo (P<0.001), and reduced the percentage of oxidized CoQ10 (P<0.001)
- Serum NOx increased significantly in subjects receiving Ubiquinol (P=0.016) versus placebo
- Increase in NOx was dose-independent (no significant difference between the 100 mg and 200 mg Ubiquinol-treated groups) (P=0.049)
- LDL oxidation lag time improved significantly in those receiving 200 mg/day Ubiquinol (P=0.017) versus placebo
The improvement in endothelial function with Ubiquinol was positively correlated with increased NOx concentration (P=0.012) and increased LDL lag time over the course of the study (P=0.031)
An 8-week, randomized, double-blind trial
Patients were healthy with mild-to-moderate dyslipidemia
Ubiquinol significantly improved endothelial function in cardiac patients with reduced ejection fraction3
In a separate small, double-blind, placebo-controlled pilot study of 14 patients with HFrEF (heart failure with reduced ejection fraction), Ubiquinol 400 mg/day for 3 months provided significant improvement in peripheral endothelial function (EF)
- Peripheral endothelial function was assessed using the reactive hyperemia index (RHI)
- RHI significantly improved with Ubiquinol (P=0.026) but not with placebo (P=0.198)